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TGF-b1Abstract Rationale: Chronic obstructive pulmonary disease (COPD) is characterized by progres-
sive airﬂow limitation that is associated with an enhanced inﬂammatory response in the airways and
the lung. The remodeling process in COPD is greatly under the inﬂuence of growth factors. Lung
ﬁbroblasts in COPD demonstrated alterations in its functional capacity that is mediated by
TGF-b1, therefore, could play a role in the pathogenesis of COPD. Fibrocytes are bone marrow
derived cells that migrate to the injured sites and differentiate into ﬁbroblast-like cells.
Objectives: To test the hypothesis that assay of circulating ﬁbrocytes may provide a biomarker
for exacerbation and severity of COPD.
Methods: Fibrocytes were deﬁned by ﬂow cytometry and quantiﬁed in ﬁfty male patients with
stable COPD and during exacerbation. We investigated the clinical and prognostic value of ﬁbro-
cytes by comparison with standard clinical parameters. Thirteen healthy subjects were selected as
control.
Results: Fibrocytes were signiﬁcantly elevated in stable COPD patients (n= 25), with a further
increase during exacerbation (n= 25; P< 0.001 vs. control subjects n= 13). Correlation analysis
between ﬁbrocyte counts and mMRC score, 6-MWT, BODE index, arterial oxygen saturation,
pre- and post-bronchodilator FEV1/FVC, FEV1, FVC and FEF25–75 showed a direct relationship
in COPD patients. There was a direct correlation between ﬁbrocytes with the mMRC score and the
serum levels of TGF-b1 only in COPD patients in exacerbations (n= 25).
Conclusions: Fibrocytes are an indicator of COPD exacerbation and might be useful as a clinical
(bio) marker for disease progression.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.Introduction
Chronic obstructive pulmonary disease (COPD) is a major
cause of morbidity and mortality throughout the world. It is
806 S. Kaddah et al.a common preventable and treatable disease characterized by
persistent airﬂow limitation that is usually progressive and
associated with an enhanced chronic inﬂammatory response
in the airways and the lung to noxious particles or gases. Exac-
erbations and co-morbidities contribute to the overall severity
in individual patients [1]. Worldwide, the most commonly
encountered risk factor for COPD is tobacco smoking; current
concepts suggest that cigarette smoke leads to an abnormal
inﬂammatory response in the lower respiratory tract that, in
turn, leads to tissue damage and destruction [2]. The peri-bron-
chiolar ﬁbrosis, which develops in the small airways, is
believed to be a response to this injury [3]. There are several
anatomic lesions that contribute to the reduced airﬂow found
in COPD patients. These include accumulation of mucous
secretions, peri-bronchiolar ﬁbrosis, narrowing of small air-
ways and destruction of alveolar walls, which is the deﬁning
characteristic of emphysema [4,5]. Destruction of alveolar
walls is believed to result from tissue destruction in excess of
the capacity of the lung to repair cigarette smoke – induced
damage [5,6].
Fibroblasts are believed to be the major cells responsible for
the production and maintenance of extracellular matrix
(ECM). Alterations in ﬁbroblast functional capacity, there-
fore, could play a role in the pathogenesis of pulmonary
emphysema. Lung ﬁbroblasts from patients with COPD dem-
onstrated less activity in several in vitro measures associated
with tissue repair. These appeared to be mediated by decreased
sensitivity to transforming growth factor-b [6].
Fibrocytes were identiﬁed in 1994 as spindle-shaped cells
that are likely bone marrow derived. They migrate to sites of
tissue injury and can differentiate into ﬁbroblast-like cells [7].
A unique feature of ﬁbrocytes is that they are circulating in
the blood stream and are capable of producing ECM compo-
nents [8]. They express a variety of mesenchymal markers
including collagen-1, the leukocyte marker CD45, and the
hematopoietic stem cell marker CD34 [7], which is down-regu-
lated with recruitment of the cell to the tissue [9]. The proﬁb-
rotic cytokine transforming growth factor-b (TGF-b1)
stimulates ﬁbrocytes to express a-smooth muscle actin, a typi-
cal but nonspeciﬁc myoﬁbroblast marker [10], supporting a
potential role of these cells in myoﬁbroblast differentiation.
Although ﬁbrocytes participate in wound repair, tissue regen-
eration, and angiogenesis in a positive manner [11,12], they
may be negatively involved in the progression of several pul-
monary diseases [13,14].
Treatment of COPD is now aimed at immediately relieving
and reducing the impact of symptoms, as well as reducing the
risk of future adverse health effects such as exacerbations [1].
In COPD, the most common medications prescribed include
bronchodilators and glucocorticoids. Despite considerable
research effort in deﬁning the effects of glucocorticoid receptor
activation in regulating leukocyte function, little is known
about its role in modulating ﬁbrocytes. Current evidence sug-
gests that cellular responses to glucocorticoids in ﬁbrocytes
may differ from those observed in leukocytes [15].
We hypothesized that in COPD patients with exacerba-
tions, there could be an increased number of circulating ﬁbro-
cytes compared with stable COPD patients.
Therefore, the objective of our study was to quantify circu-
lating ﬁbrocytes in COPD patients during stable disease and in
exacerbations, also to determine a possible biomarker role of
ﬁbrocytes in COPD, and ﬁnally to examine a potentialcontribution role of TGF-b1 and treatment with glucocorti-
coids on ﬁbrocytes.Subjects and methods
A prospective study that was conducted at the Chest Depart-
ment, Kasr El-Aini hospital, Cairo University. Fifty male
patients with conﬁrmed diagnosis of COPD (25 stable COPD
patients and 25 COPD patients in exacerbation), and 13
healthy male volunteers with no history of smoking as a con-
trol group, were involved in the study. Diagnosis of COPD
was based on the clinical history, physical examination and
spirometric measurements (the presence of a post-bronchodila-
tor FEV1/FVC< 0.70) which conﬁrms the presence of persis-
tent airﬂow limitation according to the Global Initiative for
Chronic Obstructive Lung Disease GOLD 2014 [1]. COPD
exacerbation is deﬁned according to GOLD 2014 by an acute
worsening of the patient’s condition from stable state and
beyond normal day-to-day variations, which presents with
worsened dyspnea; worsened sputum volume and/or change
in its color; or any combination of these symptoms, and
requires a change in regular medication [1].
Exclusion criteria were: patients with history of asthma,
IPF, cystic ﬁbrosis or active pulmonary tuberculosis. This
study was approved by the Human Ethical Committee of
Cairo University and all subjects gave informed consent.
The following data were collected:
Clinical data: Age and body mass index (BMI) were
obtained for all groups. Smoking status, modiﬁed British Med-
ical Research Council scale (mMRC) for dyspnea, presence of
co-morbidities, number of previous exacerbations, and steroid
therapy in COPD patients, were collected.
6-Minute Walk Test (6-MWT): 6-Minute Walk Distance
and measurement of oxygen saturation using pulse oximetry
(pre and post 6-MWT), were assessed for all groups. The test
was performed according to American Thoracic Society
guidelines [16]. For the exacerbation group, it was performed
after one week.
Results of spirometry and grading of severity: Measurement
of the forced expiratory volume in the ﬁrst second (FEV1),
forced vital capacity (FVC), FEV1/FVC, forced expiratory
ﬂow 25–75% (FEF25–75%) were obtained for all groups.
The results of post-bronchodilator were obtained only for
the COPD group. It was performed after one week for patients
in exacerbation.
COPD grading according to the severity of airﬂow limita-
tion (based on Post-Bronchodilator FEV1) was as follows;
GOLD 1(mild) FEV1P 80% predicted, GOLD 2(moderate)
50% 6 FEV1 < 80% predicted, GOLD 3(severe) 30% 6
FEV1 < 50% predicted, GOLD 4(very severe) FEV1 < 30%
predicted [1].
Calculation of the BODE index: BODE index (body mass
index, airﬂow obstruction, dyspnoea, and exercise capacity)
which is a multistage functional scoring system for COPD
comprising an assessment of symptoms, a surrogate of the
nutritional state, and exercise capacity together with the
spirometric measure of airﬂow (FEV1) [17]. This multidimen-
sional grading system was shown to be superior over the
FEV1-based GOLD classiﬁcation [18] for predicting hospital-
ization and the risk of death among patients with COPD
[17,19] (Table 1).
Table 1 Scoring the BODE index.
0 1 2 3
FEV1 % pred P65 50–64 36–49 635
6MWD (m) P350 250–349 150–249 6149
mMRC 0–1 2 3 4
BMI (kg.m2) >21 621
Total BODE index score = 0–10 units.
(FEV1 % pred = predicted amount as a percentage of the forced
expiratory lung volume in the ﬁrst second; 6MWD= six minute
walking distance; mMRC=modiﬁed medical research council
dyspnea scale; BMI = body mass index) [17].
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for COPD patients. Pao2 < 60 mmHg with or without
Paco2 > 50 mmHg when breathing room air indicates severity
of an exacerbation.
Separation of ﬁbrocyte from peripheral blood samples:
Thirty milliliters of whole blood was obtained on the routine
evaluation of stable COPD patients and the control group;
and within 24–48 h for the COPD patients with acute exacer-
bation. Peripheral blood mononuclear cells (PBMCs) were
separated from fresh whole blood by standard density-gradient
centrifugation, using Ficoll-Paque (Pharmacia Biotechnology,
Uppsala, Sweden) at 500 rpm for 20 min at room temperature.
After centrifugation, the top plasma layer (i.e. the mononu-
clear cells at the interface) was harvested and kept frozen in
sodium chloride lysis solution for further analysis for TGF-b1.
Then, the precipitation was diluted 1:1 with sterile
phosphate buffered saline (PBS) before to layering over the
Ficoll-Paque. The PBMCs at the interface were carefully aspi-
rated with spinning at 1600 rpm for 30 min. The cells were then
washed three times with PBS and resuspended in Dulbecco’s
Modiﬁed Eagle Medium (DMEM). The nonadherent
mononuclear cell fraction was separated by centrifugation,
resuspended in DMEM and mixed with red cell lysis solution
to deplete red cells by a second Ficoll-Paque centrifugation.
T cells were further depleted with anti-CD34 monoclonal anti-
body using cell sorting apparatus [20].
Magnetic separation: Freshly isolated peripheral blood cells
were stained with anti-CD45 Antibodies coupled to magnetic
beads (Miltenyi Biotech, Auburn, CA). Labeled cells were then
sorted by binding the cell population to positive selection col-
umns using a SuperMacs apparatus (Miltenyi Biotech) accord-
ing to the manufacturer’s instructions. Cells are then washed
extensively. CD45 positive cells are retained on the column
and can be removed by ﬂushing the column with buffer once
it is removed from the magnetic ﬁeld. CD45 positive cells are
collected in the original ﬂow. Their number was determined
by counting the cells that were retained on the column by a
hemocytometer. Then, ﬂow cytometry staining on this popula-
tion conﬁrms that these cells were CD45 positive cells [20].
Flow cytometric analysis: Frozen samples were thawed rap-
idly in warm water to room temperature and washed in 40 ml
of FACS buffer (BD Pharmingen, San Diego, CA), and then
centrifuged at 1500 rpm for 5 min. Cells were washed and
ﬁxed/permeabilized using the Cytoﬁx/Cytoperm kit from
(BD Pharmingen). Fibrocytes were detected by ﬂow cytometry
(FACScan; BD Biosciences, Mountain View, CA), using both
phycoerythrin (PE)-conjugated anti-CD34 or (PE)-conjugated
anti-CD45 (clone RAM34, BD Pharmingen). Thus ﬁbrocytenumbers were expressed as a percentage of total leukocyte
counts [21].
Collagen1 mRNA analysis: Cellular mRNA was prepared
using Trizol reagent (Invitrogen) according to the manufac-
turer’s instructions. Gene expression for col 1 was determined
by Real-time PCR (RT-PCR) ampliﬁcation which was carried
out using 10 lL ampliﬁcation mixtures containing Power
SYBR Green PCR Master Mix (Applied Biosystems, Foster
City, CA USA), equivalent to 8 ng of reverse-transcribed
RNA and 300 nM primers, the sequences of PCR primer pairs
used for each gene were as follows:col 1 sense, TGGTGC
CAAGGGTCTCACTGGC; col 1 anti-sense, GGACCTTG
TACACCACGTTCACC; beta actin sense, GTGGGGCTCC
CCAGGCACCA; beta actin anti-sense, GCTCGGCCGTG
GTGGTGAAGC. Reactions were run on an ABI PRISM
7900 HT detection system (Applied Biosystems). PCR reac-
tions consisted of 95 C for 10 min (1 cycle), 94 C for 15 s,
and 60 C for 1 min (40 cycles). Data were analyzed with the
ABI Prism sequence detection system software and quantiﬁed
using the v1Æ7 Sequence Detection Software from PE Biosys-
tems (Foster City, CA). Relative expression of studied genes
was calculated using the comparative threshold cycle method.
All values were normalized to the beta actin gene [22].
Measurement of TGF-b1: Serum TGF-b1 was measured by
using ELISA (quantikine R&D system USA) according to
the manufacturer‘s instructions [23].
Statistical methods
Data were analyzed using SPSS (Statistical Package for Social
Sciences; SPSS Inc., Chicago, IL, USA) version 17 for Micro-
soft windows. Numerical data were presented as mean ± SD.
Categorical data were presented as percentage. Comparisons
between 3 groups (control, stable, and exacerbation) of numer-
ical data were conducted using ANOVA (ANALYSIS OF
VARIANCE) or non-parametric Kruskal–Wallis test as
appropriate, paired comparisons were conducted using
Tukey’s test. Comparisons between 2 groups (stable and
exacerbation) of numerical data were conducted using Stu-
dent’s t-test or non-parametric Mann–Whitney U test as
appropriate. Comparisons between 2 groups (stable and
exacerbation) of categorical data were conducted using the
Chi-square test. Pearson correlation was used for correlation
analysis. Probability (p-value) < 0.05 was considered signiﬁ-
cant and highly signiﬁcant if P-value < 0.001.
Results
Patients’ characteristics
In total, 25 patients with stable COPD [15 patients were
GOLD 1 and 2 (60%) and 10 patients were GOLD 3 and 4
(40%)], 25 COPD patients in exacerbations and 13 healthy
control subjects were included in the study. Patients’ character-
istics are shown in Table 2.
The mean age of the patients with stable COPD was
56.5 ± 10.2 whereas, the mean age of the COPD patients in
exacerbations and normal subjects were 60.2 ± 7.9 and
35.1 ± 8.3, respectively. Also, there was no statistical differ-
ence in the mean of the BMI between the 3 groups
(P= 0.578).
Table 2 Clinical characteristics of subjects.
Normal subjects COPD, stable COPD, exacerbations p- value
(n= 13) (n= 25) (n= 25)
Age, year 35.1 ± 8.3 56.5 ± 10.2 60.2 ± 7.9 0.045
BMI 26.1 ± 4.7 24.3 ± 4.6 25.1 ± 5.7 0.578
No. of cigarettes 0 22.0 ± 10.0 24.8 ± 10.5 0.3
Duration of smoking 0 25.5 ± 7.4 32.5 ± 6.3 0.001
Smoking index 0 574.4 ± 346.0 794.4 ± 308.4 0.004
mMRC scale 0 2.0 ± 0.9 3.0 ± 0.8 <0.001**
BODE 0 3.2 ± 2.5 6.4 ± 2.0 <0.001**
No. of exacerbations 0 1.7 ± 1.1 3.4 ± 2.0 0.001
6-MWT distance 489.2 ± 38.4 372.0 ± 86.2 238.8 ± 82.0 <0.001*
SO2 pre-6-MWT 97.7 ± 0.6 95.6 ± 1.6 92.0 ± 4.1 <0.001
*
SO2 post-6-MWT 97.8 ± 0.8 94.70 ± 2.2 88.9 ± 5.9 <0.001
*
Paco2 mmHg 37.5 ± 4.6 44.7 ± 8.6 0.001
Pao2 mmHg 72.4 ± 8.0 59.1 ± 5.9 <0.001
**
Arterial SO2% 95.4 ± 1.9 90.3 ± 3.0 <0.001
**
Pre-bronchodilators
FEV1/FVC 90.2 ± 7.2 58.5 ± 10.5 53.2 ± 13.0 <0.001
*
FVC, %pred 86.0 ± 10.9 73.5 ± 21.3 45.5 ± 11.9 <0.001*
FEV1, %pred 92.7 ± 11.7 56.0 ± 22.1 31.7 ± 11.9 <0.001
*
FEF25–75,%pred 97.5 ± 22.0 30.6 ± 17.2 17.6 ± 11.8 <0.001*
Post-bronchodilators
FEV1/FVC 58.5 ± 10.5 53.2 ± 13 0.118
FVC, %pred 78.4 ± 21.4 49.5 ± 12.2 <0.001**
FEV1, %pred 58.5 ± 21.2 33.4 ± 12.5 <0.001
**
FEF25–75,%pred 32.9 ± 17.3 18.0 ± 11.4 0.001
Deﬁnition of abbreviations: SO2 = oxygen saturation; Paco2 = arterial carbon dioxide tension; Pao2 = arterial oxygen tension, FVC= forced
vital capacity; FEV1 = forced expired volume in the ﬁrst second; FEF= forced expiratory ﬂow. Data are expressed as mean ± standard
deviation (SD).P-value < 0.05 is considered signiﬁcant.
P-value < 0.001 is considered of high statistical signiﬁcance.
* P-value < 0.001, compared with patients of COPD (stable and in exacerbations) and normal subjects.
** P-value < 0.001, compared with patients of COPD and those in exacerbations.
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patients with exacerbation than stable COPD (794.4 ± 3,
574.4 ± 3; P= 0.004). There were 7/25 (28%) patients with
different co-morbidities in the stable COPD cases compared
to 12/25 (48%) patients in those with exacerbations and with
no signiﬁcant difference (P= 0.145). There was statistical dif-
ference between the number of previous exacerbations between
the stable COPD patients and those in exacerbations
(P= 0.001). As regards therapy, there were 19 COPD patients
in exacerbations receiving intravenous corticosteroids.
There were a marked statistical difference in the dyspnea
mMRC score, BODE index, arterial oxygen tension (Pao2),
arterial oxygen saturation (SO2) and the post-bronchodilator
FVC and FEV1 between patients with stable COPD and those
in exacerbations (P< 0.001).
There was a highly statistical signiﬁcant difference between
the three groups of the study as regards the following; the
mean distance of the 6MWT, the mean of the oxygen satura-
tion before and after the 6-MWT, and the mean of the pre-
bronchodilator spirometry measures (FEV1/FVC ratio, FVC
(%predicted value), FEV1 (%predicted value), FEF25–75
(%predicted value), (P< 0.001).
Fibrocyte quantiﬁcation
The absolute counts per milliliter of blood ﬁbrocytes was
highly signiﬁcantly increased in the blood of COPD patientsin exacerbations (4.2 ± 2.0 · 104 cells/ml, n= 25; P< 0.001)
compared to patients with stable COPD (1.0 ± 0.5 · 104
cells/ml, n= 25) and the healthy control subjects
(0.7 ± 0.27 · 104 cells/ml, n= 13). Similarly, when expressed
as percentage of circulating ﬁbrocytes, deﬁned as CD34,
CD45 and collagen-1–expressing cells they were also highly
signiﬁcantly increased in the blood of COPD patients in exac-
erbations (25.2 ± 5.7, 19.7 ± 5.9 and 0.97 ± 0.49, respec-
tively) compared to stable COPD patients (13.6 ± 3.7,
8.9 ± 2.7 and 0.38 ± 0.24, respectively) and the healthy con-
trol subjects (9.8 ± 3.5, 8.1 ± 2.0 and 0.14 ± 0.06, respec-
tively); P< 0.001 (Table 3). Also, the serum levels of TGF-
b1 were signiﬁcantly higher in COPD patients with exacerba-
tions (440.6 ± 164.0 pg/ml) than in normal subjects
(121.5 ± 18.7 pg/ml) and patients with stable COPD
(190.5 ± 21.3 pg/ml); P< 0.001 (Table 3).
Moreover, when we compared the percentage of CD34,
CD45, collagen-1–expressing cells, the absolute counts of
blood ﬁbrocytes and the serum levels of TGF-b1
(25.24 ± 5.71, 19.73 ± 5.94, 0.97 ± 0.49, 4.21 ± 1.99 and
440.61 ± 163.99, respectively) in the blood of COPD patients
in exacerbations to stable COPD patients either GOLD 1 and
2 (mild-moderate) [12.75 ± 3.23, 8.71 ± 2.48, 0.29 ± 0.19,
0.83 ± 0.31 and 185.93 ± 21.78, retrospectively] or GOLD 3
and 4 (severe-very severe) [14.93 ± 4.15, 9.12 ± 3.07,
0.53 ± 0.23, 1.23 ± 0.31 and 197.46 ± 19.62, retrospectively]
all were signiﬁcantly highly elevated; (P< 0.001) (Table 4).
Table 3 Show the level of different markers in the COPD (stable and in exacerbations) patients and the control group.
Normal subjects COPD, stable COPD, exacerbations p- value
(n= 13) (n= 25) (n= 25)
b b a
CD34% Mean ± SD 9.8 ± 3.5 13.6 ± 3.7 25.2 ± 5.7 <0.001
Median 9.3 12.6 26.1
(Min–Max) (6.1–19.3) (8.1–20.4) (16.4–34.3)
CD45% Mean ± SD 8.1 ± 2.0 8.9 ± 2.7 19.7 ± 5.9 <0.001
Median 8.1 9.3 18.5
(Min–Max) (6.1–12.1) (4.1–12.9) (12.1–31.4)
Collagen-1–expressing cells% Mean ± SD 0.14 ± 0.06 0.38 ± 0.24 0.97 ± 0.49 <0.001
Median 0.15 0.24 0.83
(Min–Max) (0.05–0.24) (0.13–0.91) (0.24–2.03)
Fibrocyte number (·104 cells/ml) Mean ± SD 0.7 ± 0.27 1.0 ± 0.5 4.2 ± 2.0 <0.001
Median 0.6 0.9 4.2
(Min–Max) (0.3–1.2) (0.4–2.1) (1.2–7.0)
TGF-b1 (pg/ml) Mean ± SD 121.5 ± 18.7 190.5 ± 21.3 440.6 ± 164.0 <0.001
Median 118 194 394.5
(Min–Max) (96.2–164.3) (148.2–219.2) (194.2–659.1)
Statistics having different letters are considered of highly statistical difference (p-value < 0.001), i.e. COPD patients in exacerbations compared
to patients with stable COPD and normal subjects.
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blood were highly signiﬁcantly increased in the blood of
COPD patients in exacerbations receiving intravenous steroids
(4.4 ± 1.9 · 104 cells/ml, n= 19; P< 0.001) compared to
those not receiving intravenous steroids (1.5 ± 1.4 · 104 cells/
ml, n= 31). However, there was no statistical difference when
comparing the absolute counts of blood ﬁbrocytes in COPD
patients with different co-morbidities (3.1 ± 2.4 · 104 cells/
ml, n= 19; P= 0.49) to those without co-morbidities
(2.2 ± 2.0 · 104 cells/ml, n= 31).
Correlation between ﬁbrocyte counts and clinical parameters
Correlation analysis between ﬁbrocyte counts and; number of
exacerbations, dyspnea mMRC score, BODE, the 6-MWT, theTable 4 Show the level of different markers in stable COPD patients
very severe]) and COPD patients in exacerbation.
COPD, GOLD 1
(n= 15)
b
CD34% Mean ± SD 12.75 ± 3.23
Median 12.3
(Min–Max) (9.20–19.20)
CD45% Mean ± SD 8.71 ± 2.48
Median 9.1
(Min–Max) (4.10–12.20)
Collagen-1–expressing cells% Mean ± SD 0.29 ± 0.19
Median 0.22
(Min–Max) (0.13–0.69)
Fibrocyte number (·104 cells/ml) Mean ± SD 0.83 ± 0.31
Median 0.82
(Min–Max) (0.41–1.50)
TGF-b1 (pg/ml) Mean ± SD 185.93 ± 21.78
Median 193.6
(Min–Max) (148.20–214.20)
Statistics having different letters are considered of highly statistical differe
to stable COPD patients GOLD 1 and 2 and GOLD 3 and 4.oxygen saturation before and after the 6-MWT arterial oxygen
tension (Pao2), arterial oxygen saturation (SO2), pre- and post-
bronchodilator FEV1, FVC and FEF25–75 showed a direct
relationship with these parameters in both stable COPD
patients and those in exacerbations (50 patients) (Fig. 1).
Also, there was a positive correlation between ﬁbrocyte
counts and CD34%, CD45%, % of collagen-1–expressing cells
and the serum levels of TGF-b1 in both stable COPD patients
and those in exacerbations (50 patients) (Fig. 1).
To assess whether ﬁbrocyte counts would be different
depending on the state of COPD patients, correlation analysis
between ﬁbrocyte counts and all the above parameters were
calculated separately in both stable COPD patients and those
in exacerbations. There were a signiﬁcant inverse correlation of
ﬁbrocyte counts with post-bronchodilator FEV1 and a(GOLD 1 and 2 [mild and moderate], GOLD 3 and 4 [severe and
&2 COPD, GOLD 3&4 COPD, exacerbations p- value
(n= 10) (n= 25)
b a
14.93 ± 4.15 25.24 ± 5.71 <0.001
14.9 26.1
(8.10–20.40) (16.40–34.30)
9.12 ± 3.07 19.73 ± 5.94 <0.001
9.8 18.5
(4.20–12.90) (12.10–31.40)
0.53 ± 0.23 0.97 ± 0.49 <0.001
0.58 0.83
(0.21–0.91) (0.24–2.03)
1.23 ± 0.31 4.21 ± 1.99 <0.001
1.1 4.2
(0.62–2.10) (1.20–7.1)
197.46 ± 19.62 440.61 ± 163.99 <0.001
204.6 394.5
(157.20–219.20) (194.20–659.10)
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Figure 1 (a) Correlation of ﬁbrocyte counts and Post bronchodilator FEV1 (b) correlation of ﬁbrocyte counts and mMRC (c)
correlation of ﬁbrocyte counts and BODE (d) correlation of ﬁbrocyte counts and TGF-b1 in COPD patients (n= 50). Two tailed Pearson
test was used. All correlations were signiﬁcant at the level 0.01 level (2-tailed).
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COPD patients. Moreover in the exacerbation group the same
correlations were present; however they did not reach a statis-
tical signiﬁcance (Fig. 2). Also there was no difference in cor-
relation of ﬁbrocyte counts with post-bronchodilator FVC,
and the 6-MWT when comparing stable COPD patients and
those in exacerbations. However, there was a direct correlation
between ﬁbrocyte counts with the mMRC dyspnea score and
the serum levels of TGF-b1 only in COPD patients in
exacerbations (Fig. 3).
Finally, there was also no relationship between ﬁbrocytes
and age, BMI or smoking index in all COPD patients (50
patients). However, there was a correlation between age and
the number of exacerbations in both stable COPD patients
and those in exacerbations.Discussion
The main ﬁnding of our study was the presence of increased
percentage of CD34, CD45, Collagen-I expressing cells,
numbers of circulating ﬁbrocytes and elevated serum levels of
TGF-b1 in the peripheral blood of COPD patients in exacerba-
tions compared to stable COPD patients and normal subjects
with direct correlation between ﬁbrocyte counts and the serum
levels of TGF-b1 only in COPD patients in exacerbations.In a study done by Togo et al. [6], they cultured ﬁbroblasts
from lung tissue obtained from individuals undergoing thora-
cotomy and were characterized in vitro. They found that ﬁbro-
blasts from patients with COPD produced more TGF-b1
compared with similarly aged control subjects with similar
smoking histories. They concluded that ﬁbroblasts from
patients with COPD manifested reduced response to TGF-b1
and have diminished repair responses that could contribute
to the development of emphysema in these subjects. They also
added that the mechanisms that account for the differences in
ﬁbroblast function in the subjects with COPD compared with
the control subjects are not yet deﬁned and that cigarette
smoke exposure is unlikely to account for the differences,
because the two groups had similar smoking histories; despite
the evidence that acute exposure of ﬁbroblasts to cigarette
smoke has been reported to inhibit ﬁbroblast repair functions
[24,25]. In our study, we also found that there was no correla-
tion between ﬁbrocytes and the smoking index in COPD
patients.
Fibrocytes have been found in patients with various ﬁbrotic
disorders and are involved in the pathogenesis of bronchial
asthma [21] and lung ﬁbrosis [26]. Wang et al. [27] found
increased numbers of ﬁbrocytes and increased levels of
TGF-b1 in the serum of patients with chronic obstructive
asthma compared with asthmatic patients with normal
lung function and normal subjects. They found a signiﬁcant
Figure 2 (a) Correlation of ﬁbrocyte counts and BODE in
COPD patients in exacerbations (n= 25). (b) Correlation of
ﬁbrocyte counts and BODE in stable COPD patients (n= 25).
Two tailed Pearson test was used. Correlations were signiﬁcant at
the level 0.01 level (2-tailed). There was no difference in correla-
tion between stable COPD patients and those in exacerbations.
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Figure 3 (a) Correlation of ﬁbrocyte counts and TGF-b1 in
COPD patients in exacerbations (n= 25). (b) Correlation of
ﬁbrocyte counts and TGF-b1 in stable COPD patients (n= 25).
Two tailed Pearson test was used. Positive correlation was
signiﬁcant at the level 0.01 level in COPD patients in exacerbations
(n= 25) (2-tailed).
Circulating ﬁbrocytes as indicators of pulmonary disease 811correlation between the percentage of circulating ﬁbroblasts
and serum TGF-b1 in their patients with chronic obstructive
asthma and the yearly decline in FEV1. This ﬁnding is not sur-
prising because TGF-b1 plays an important role in the differ-
entiation of ﬁbrocyte-like progenitor cells and enhances the
differentiation of CD45, CD34 and Collagen-I expressing cells
into ﬁbroblasts/myoﬁbroblasts. In these cells, TGF-b1 also
stimulates expression of a number of proinﬂammatory and
ﬁbrogenic cytokines, such as tumor necrosis factor (TNF-a),
platelet-derived growth factor (PDGF), IL-1b, or IL-13,
thereby further enhancing collagen production and thickening
of the sub-basement membrane observed in patients with asth-
ma. The mechanism by which remodeling may link to the pro-
gressive decline in lung function leading to chronic airﬂow
obstruction is seen in some patients with asthma [28,29].
Regarding that the clinical management and staging of
COPD which relies on monitoring of pulmonary function tests
(PFT) and exercise capacity, usually by 6MWT we correlated
the number of ﬁbrocytes to those parameters. we found thatthere was a direct correlation between the number of ﬁbrocytes
and the pre- and post-bronchodilator FEV1/FVC, FEV1,
FVC, FEF25–75, 6-MWT, the oxygen saturation before and
after the 6-MWT in all COPD patients but when correlating
those parameters to the state of COPD there was no difference
between stable COPD and patients in exacerbations.
Recently, the incorporation of the subjective variable ‘dysp-
nea’ and the individual exercise capacity, the BODE index was
used more as it is thought that it is closely related to the
individual subjective consequences of COPD than lung
function alone [17–19]. In our study there was a positive corre-
lation between the number of ﬁbrocytes and the mMRC
score and BODE in all COPD patients. But when correlating
those parameters to the state of COPD only the mMRC
score showed a direct relationship to COPD patients in
exacerbations.
Also, Moeller et al. [30] studied the effect of ﬁbrocytes as an
indicator of poor prognosis in IPF patients. They demon-
strated a threefold increase in circulating ﬁbrocytes (CD45+-
812 S. Kaddah et al.Col-1+ cells) in patients with stable IPF compared with
healthy control individuals. They also found that during epi-
sodes of acute disease exacerbation, ﬁbrocyte counts further
increased to an average of 15% of peripheral blood leukocytes
and fell back to pre-exacerbation levels in the patients who
recovered. They also compared their ﬁndings to a study on a
small group of patients with IIP, who had increased ﬁbrocytes
in their circulation during stable disease [31].
When Nihlberg et al. [29] studied the effect of steroids on
ﬁbrocytes in asthmatic patients, they found that in steroid-
naive patients with mild asthma, an increased number of ﬁbro-
cytes was observed in the bronchial mucosa as well as in the
bronchoalveolar lavage ﬂuid; and the number of submucosal
ﬁbrocytes had been correlated with the thickness of the sub-
basement membrane. However, in our study, ﬁbrocytes were
signiﬁcantly increased in the blood of COPD patients receiving
intravenous steroids, a ﬁnding that could be explained that
those patients were in exacerbations with already elevated
counts of blood ﬁbrocytes.
To date, FEV1 changes over time may be the best func-
tional marker in COPD, even if the change may not necessarily
reﬂect progression of the underlying disease. Our study was
able to demonstrate a potential relationship between mMRC
score, FEV1 changes, 6MWT, BODE, oxygen saturation and
the change in ﬁbrocyte percentage in COPD patients. Even sta-
ble COPD patients GOLD 3 and 4 showed a higher ﬁbrocyte
counts and in these patients; though lacking clinical signs of
deterioration, they might be at greater risk of exacerbation
or rapid progression.
Also, we speculate that the increase in ﬁbrocyte counts may
precede the clinical and functional decline, but because of the
relatively low subject numbers, larger and long-term studies
are needed to examine this hypothesis.
Despite numerous in vitro and in vivo studies, the biology of
mesenchymal progenitor cells and circulating ﬁbrocytes is
complex and incompletely understood. On the one hand, they
seem to be able to produce cytokines, growth factors and extra
cellular matrix ECM proteins [32,33]. On the other hand, there
is evidence that these cells are involved in abnormal scar for-
mation in models of wound repair, possibly through ﬁbro-
cyte-mediated T-cell activation and could play a role in the
pathogenesis of pulmonary emphysema [34–36]. However,
the present study has conﬁrmed that ﬁbrocytes are present in
the blood of patients with COPD and even more so during
acute exacerbation of the disease, which allows the examina-
tion of their potential as biomarkers, regardless of understand-
ing their biological properties in detail.
In conclusion, we found increased counts of ﬁbrocytes in
the blood of COPD patients with exacerbations compared with
stable COPD patients and healthy control subjects. Fibrocytes
did not correlate with clinical parameters such as age, BMI
and smoking index but were predictive of severity as regards
mMRC score, FEV1 changes, BODE, 6MWT and oxygen sat-
uration. This study suggests a potential role for assaying ﬁbro-
cytes as an independent prognostic biomarker for COPD;
however, larger studies are needed to conﬁrm or refute these
ﬁndings.
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